Healthcare · Industry
Biotechnology - List & Prices (656 stocks)
By market cap Page 14 of 14 Prices: Sep 4, 2026 close
| Company | Ticker | Price | Mkt cap | P/E | Div yield |
|---|---|---|---|---|---|
| Lyra Therapeutics, Inc. | LYRA | $0.20 | $354.98K | — | |
| XOMA Royalty Corp | XOMAO | $25.00 Jul 21, 2026 | — | 25.0 | 8.38% |
| Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock | FBIOP | $18.75 | — | — | |
| Psyence Biomedical Ltd. | PBM | $4.54 | — | — | |
| Estrella Immunopharma, Inc. | ESLAW | $0.08 Aug 24, 2026 | — | — | — |
| XOMA Royalty Corp | XOMAP | $24.98 Jul 21, 2026 | — | 25.0 | 8.63% |
LYRA
$0.20 Lyra Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $354.98K
- P/E
- unprofitable
XOMAO
$25.00 XOMA Royalty Corp
Healthcare / Biotechnology
- P/E
- 25.0
- Dividend Yield
- 8.38%
FBIOP
$18.75 Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Healthcare / Biotechnology
- P/E
- unprofitable
PBM
$4.54 Psyence Biomedical Ltd.
Healthcare / Biotechnology
- P/E
- unprofitable
ESLAW
$0.08 Estrella Immunopharma, Inc.
Healthcare / Biotechnology
XOMAP
$24.98 XOMA Royalty Corp
Healthcare / Biotechnology
- P/E
- 25.0
- Dividend Yield
- 8.63%
Showing 651–656 of 656 · ranked by market capitalization
Where the trailing year was a loss, P/E appears as “unprofitable”; a dash is missing data.